Immunomic Therapeutics to Sponsor and Present at CHCI Health Summit February 26, 2019 04:05 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. announced today that its’ Senior Vice ...
February 06, 2019 05:00 PM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI), a privately held, Maryland-based biotechnology company, announced today that the company has granted Japanese animal ...
November 15, 2018 06:15 AM Eastern Standard Time SAN DIEGO--(BUSINESS WIRE)--Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy ...
November 07, 2018 06:00 AM Eastern Standard Time NEW ORLEANS--(BUSINESS WIRE)--On Friday, November 16, Immunomic Therapeutics Inc. (ITI) Scientist Amit Adhikara will present at the Society for NeuroOncology 2018 Annual ...
ITI Presents on Functional Evaluation of Isoforms Present in pDNA Vaccines at Aldevron’s Breakthrough Symposium
ITI's Michael Connolly, Manager of Process Development, presents a poster titled, "Functional evaluation of isoforms present in pDNA vaccines" at Aldevron's corporate offices located in Fargo, North Dakota A detailed abstract ...
Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit
Immunomic Therapeutics Senior Director of Corporate Development to Present at Precision Lung Cancer World R&D Summit Discussion of lysosomal targeting technology as applied in cancer immunotherapy October 26, 2018 07:30 ...
Immunomic Therapeutics CEO to Present at NYC Oncology Investor Conference To Discuss UNITE Technology Application in Oncology October 23, 2018 07:00 AM Eastern Daylight Time NEW YORK--(BUSINESS WIRE)--Immunomic Therapeutics, ...
Immunomic Therapeutics, Inc. Founder and CEO Bill Hearl Joins Rich Bendis for BioTalk Click to hear the interview: Bill Hearl Q&A Dr. Bill Hearl is the Founder and Chief Executive Officer ...
Our very own Dr. Heiland has been featured on BioBuzz. Click below to read the full Q&A Interview, as Dr. Heiland discusses our technology platform name change to UNITE and ...
Scientific American custom media and Immunomic Therapeutics, Inc. wrote this article titled, “After the Gold Rush." Immuno-oncology (IO) has seen a flood of advancements, investment deals and partnerships, but the ...
Scientific American custom media and Immunomic Therapeutics released an article titled, “The Fight Against Cancer is Increasingly Personal,” by reclassifying tumors, scientists are finding a path to genuine cancer cures. ...
Immunomic to Participate at 2018 BIO CEO & Investor Conference with Presentation and Panel Discussion
Immuno-Oncology Panel led by Scientific American February 12, 2018 07:30 AM Eastern Standard Time ROCKVILLE, Md.--(BUSINESS WIRE)--Immunomic Therapeutics (ITI), pioneering the study of investigational LAMP-based nucleic acid immunotherapy programs, ...